Join the Chronic Obstructive Pulmonary Disease group to help and get support from people like you.
Chronic Obstructive Pulmonary Disease News (Page 5)
Related terms: Chronic Obstructive Pulmonary Disease, Acute, Bronchitis, Chronic, Bronchitis with Airway Obstruction, Chronic Bronchitis, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease, COPD, Acute, COPD, Maintenance, Emphysema, Chronic Obstructive Pulmonary Disease, Maintenance, COPD
Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients with COPD
24 April 2018 – GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy...
FDA Medwatch Alert: Long-Acting Beta agonists (LABAs) and Inhaled Corticosteroids (ICS): Drug Safety Communication - Boxed Warning About Asthma-Related Death Removed
ISSUE: FDA's most prominent warning, the Boxed Warning, about asthma-related death has been removed from the drug labels of medicines that contain both an ICS and LABA. A FDA review of four large...
Sunovion Receives FDA Approval for Lonhala Magnair (glycopyrrolate) Inhalation Solution to Treat COPD
MARLBOROUGH, Mass.--(BUSINESS WIRE) December 5, 2017 --Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application...
FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of COPD
London UK – 18 September 2017 – GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single i...
Bevespi Aerosphere Approved by the FDA for Patients with COPD
25 April 2016 – AstraZeneca today announced that the US Food and Drug Administration has approved Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol indicated for the...
FDA Approves Seebri Neohaler (glycopyrrolate) for COPD
EAST HANOVER, N.J., Oct. 29, 2015 Novartis announced today that the US Food and Drug Administration (FDA) has approved Seebri Neohaler (glycopyrrolate) inhalation powder 15.6 mcg as a stand-alone...
FDA Approves Utibron Neohaler (indacaterol/glycopyrrolate) for COPD
EAST HANOVER, N.J., Oct. 29, 2015 Novartis announced today that the US Food and Drug Administration (FDA) has approved the dual combination bronchodilator Utibron Neohaler...
FDA Approves Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray for COPD
RIDGEFIELD, Conn., May 26, 2015 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto Respimat (tiotropium bromide and olodaterol) I...
FDA Approves Spiriva Respimat (tiotropium) for the Maintenance Treatment of COPD
Ridgefield, Conn., September 25, 2014 – Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Spiriva Respimat (tiotropium bromide) i...
FDA Approves Striverdi Respimat to Treat Chronic Obstructive Pulmonary Disease
July 31, 2014 – Today, the U.S. Food and Drug Administration approved Striverdi Respimat (olodaterol) inhalation spray to treat patients with chronic obstructive pulmonary disease (COPD), including...
FDA Approves Incruse Ellipta (umeclidinium) for the Treatment of COPD
London UK - 30 April 2014, GlaxoSmithKline plc today announced that the US Food and Drug Administration (FDA) has approved Incruse Ellipta (umeclidinium) as an anticholinergic indicated for the...
FDA Approves Anoro Ellipta to Treat Chronic Obstructive Pulmonary Disease
December 18, 2013 – The U.S. Food and Drug Administration today approved Anoro Ellipta (umeclidinium and vilanterol inhalation powder) for the once-daily, long-term maintenance treatment of airflow...
FDA Approves Breo Ellipta to Treat Chronic Obstructive Pulmonary Disease (COPD)
May 10, 2013 – The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of...
Horizon Pharma Announces FDA Approval of Rayos (prednisone) Delayed-Release Tablets for Rheumatoid Arthritis and Multiple Additional Indications
DEERFIELD, Ill., July 26, 2012 /PRNewswire/ – Horizon Pharma, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Rayos (prednisone) delayed-release tablets (1 mg, 2...
FDA Approves Tudorza Pressair to Treat Chronic Obstructive Pulmonary Disease
July 23, 2012 – The U.S. Food and Drug Administration today approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm (narrowing of the airways in the...
Further information
Related drug support groups
prednisone, albuterol, Symbicort, Dupixent, Trelegy Ellipta, montelukast, dupilumab, Anoro Ellipta